Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera

December 3-6, 2016; San Diego, California
Results from the phase III trial showed fewer treatment-related AEs, dose reductions, and secondary malignancies in patients receiving ropeginterferon α-2b compared with those receiving hydroxyurea.
Format: Microsoft PowerPoint (.ppt)
File Size: 502 KB
Released: December 7, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

Downloadable slides from a Clinical Care Options (CCO) video on treatment strategies for patients with lower risk myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Released: January 15, 2021

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Brief expert video from Clinical Care Options (CCO) on recommended treatment strategies for patients with lower-risk myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 15, 2021 Expired: January 14, 2022

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.